Kraj: Kanada
Język: angielski
Źródło: Health Canada
PINDOLOL
MYLAN PHARMACEUTICALS ULC
C07AA03
PINDOLOL
5MG
TABLET
PINDOLOL 5MG
ORAL
100 & 500 TABLETS
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0112362001; AHFS:
CANCELLED POST MARKET
2012-10-19
1 PRODUCT MONOGRAPH MYLAN-PINDOLOL (Pindolol Tablets, USP) 5 AND 10 MG Antihypertensive/Antianginal Agent Mylan Pharmaceuticals ULC Date of Preparation: 85 Advance Road August 19, 2010 Etobicoke, Ontario M8Z 2S6 Control#: 140702 2 PRODUCT MONOGRAPH MYLAN-PINDOLOL (Pindolol Tablets, USP) 5 AND 10 MG THERAPEUTIC CLASSIFICATION Antihypertensive/Antianginal Agent ACTIONS AND CLINICAL PHARMACOLOGY Pindolol is a 13-adrenergic-receptor-blocking agent which possesses partial agonist activity (intrinsic sympathomimetic activity - I.S.A.). It is used in the treatment of hypertension and/or the prophylaxis of angina pectoris. Hypertension The mechanism of the antihypertensive effect of pindolol has not been established. Among the factors that may be involved are: a) competitive ability to antagonize catecholamine-induced tachycardia at the 13-receptor sites in the heart, thus decreasing cardiac output b) a reduction in total peripheral resistance c) inhibition of the vasomotor centres d) inhibition of renin release by the kidneys. 3 Angina pectoris The mechanism of the antianginal effect of pindolol has not been established. Pindolol may reduce the oxygen requirement of the heart at any level of effort by blocking catecholamine- induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. However, oxygen requirements may be increased by such actions as increases in left ventricular fibre length, end diastolic pressure and the systolic ejection period. When the net effect is beneficial in patients with angina, it manifests itself during exercise or stress by delaying the onset of pain and reducing the incidence and severity of anginal attacks. In man, orally-administered pindolol is rapidly and almost completely absorbed (95%). Because of negligible hepatic first pass effect, the bioavailability of oral pindolol is high and approaches 90% of the oral dose. Maximum plasma concentrations are reached one to two hours after oral administration and the plasma half-life is ap Przeczytaj cały dokument